Article Text

PDF
024
CARDIOTOXICITY OF CHRONIC SUNITINIB TREATMENT IN NORMOTENSIVE AND SPONTANEOUSLY HYPERTENSIVE RATS
  1. I Nemeckova1,
  2. O Lencova2,
  3. E Jirkovsky2,
  4. M Adamcova3,
  5. P Nachtigal1,
  6. M Sterba2
  1. 1Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Czech Republic
  2. 2Department of Pharmacology and
  3. 3Physiology, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Czech Republic

Abstract

Aims Sunitinib is a modern multi-targeted tyrosine kinase inhibitor, which showed great promise in the treatment of human cancer. However, its chronic use may be associated with cardiotoxicity, which is poorly understood. Hence, the aim of the present study was to investigate potential cardiotoxicity of chronic sunitinib treatment in normotensive and spontaneously hypertensive rats.

Methods Spontaneously hypertensive rats (SHR) and their normotensive littermates (Wistar Kyoto, WKY) were used in the study (n=32). Sunitinib (10 mg/kg) was administered daily for 8 weeks and after a wash out period (5 days) a re-challenge for 2 and 8 weeks followed in WKY and SHR rats, respectively.

Results Sunitinib treatment induced a significant left ventricular (LV) dysfunction and decline in heart rate. This was accompanied by increased LV BNP expression, increased BNP plasma concentrations and increased lung to body weight ratio. Remarkably, no such change was found in SHR despite significantly longer duration of treatment. Moreover, sunitinib-induced cardiac dysfunction in WKY was accompanied by marked expression of numerous hypoxia-regulated genes and inflammatory molecules.

Conclusions In conclusion, our findings show different propensity of WKY and SHR animals towards sunitinib cardiotoxicity development and suggest an important role of hypoxic signaling in this process. Furthermore, possible involvement of “hibernating myocardium” in sunitinib-induced cardiac dysfunction deserves further study, particularly with respect to recently reported impairment of cardiac microvasculature.

The publication is co-financed by the European Social Fund and the state budget of the Czech Republic, project no. CZ.1.07/2.3.00/30.0061. This work was supported by project UNCE 33/2012.

  • CARDIAC PROCEDURES AND THERAPY

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.